Big pharma price-rigging scheme
Drug Retailers Demand Documents about Aggrenox “Pay for Delay” Scheme
July 31, 2017
Several drug retailers have petitioned a federal court in Connecticut to provide Federal Trade Commission (FTC) documents pertaining to drugmaker Boehringer’s alleged scheme to block generic alternatives to its stroke-prevention drug Aggrenox.
The FTC is investigating the same alleged “pay for delay” case that is the focus of the current Multi-District Litigation (MDL) case in Connecticut, and the plaintiffs argue that they have a right to see these potentially relevant documents.
In the MDL case, Barr Pharmaceuticals – acquired by Teva Pharmaceuticals in 2008 – is accused of agreeing to delay the marketing of a generic alternative to Aggrenox upon receiving a portion of Boehringer’s profits from sales of Aggrenox.
The MDL gathers 11 antitrust lawsuits that accuse Boehringer of running a $120 million pay for delay scheme.
If you believe you’re the victim of a price-rigging scheme by Big Pharma – you may be right. And you may be entitled to participate in a legal action to that effect. Contact TheLawFirm.com for a free consultation.
TheLawFirm.com’s award winning lawyers have been featured in over 50 radio and television interviews including:
Real lawyers, real results!
no recovery, no fee!